INNOVATE • INTERACT • INVEST
Platinum Partnering Sponsors:
Cancer Progress Conference 2022 Panels
Patients Front and Center
How to Catch and Treat Cancer Early
Stage of the Art in Immuno-Oncology: Beyond PDx Inhibitors – or Not So Much
The Latest Potential “Paradigm-Shifters”
ADC “The Next Generation”
Biotechs to Go It Alone - Launch Strategy for Success
How to Value Value: HEOR, HTA, ICER & Other Scary Acronyms for Oncology Developers!
What’s Hot/What’s Not for Startups in the Quasi-Post-Pandemic Oncology World?
Biotech versus Pharma Perspectives - Clinical Development Strategy
Cancer Vaccines Redux: mRNA, Oncolytic Viruses, Or Good Old-Fashioned Peptides - Is It the Target(s), Immunization Platform, Clin Dev Strategy, or All of the Above?
Does RNA Rule the World?
Degraders
Growing Pains - Navigating the Precipitous Path Towards Commercialization
Tortoises and Hares - De-risking Strategies Towards Multiplexed Candidates
Selling the Cell - Cost-benefit Considerations for Complex Therapeutics
Building on Success - Clinical and Commercial Dynamics in Heme Malignancies and Hematopoietic Transplantation
Tools of the Trade - Strategic Positioning of Emerging Cell Types, Target Discovery Engines, and Gene Engineering Tools
Battle of the Modalities: The Sequel to the Sequel - Revenge of the Nerds
Leading Companies and Institutions that attended Cancer Progress 2021
|
|
|
Since 1989, Cancer Progress is the only oncology conference that facilitates discussions of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives over three days of provocative, informative panel discussions. Pivotal topics, frank discussions, vigorous debate, opportunities for audience questions and comments, and, for the first time ever, a partnering platform to enable meaningful connections and meetings with innovators, developers and investors.
Our 33rd Annual Meeting on May 10-12, 2022 will provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference.
Testimonials
Good array of opinions and technologies. Well curated
Andrew Allen, MD, PhD, President & CEO
Gritstone OncologyAs I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!
Michael G. King, Jr., Entrepreneur in Residence
Fortress Biotech Inc.When we hear all the negatives from the experts on cell therapies and COVID—let’s think of Richard Feynman: “Science is the belief in the ignorance of the experts
Mark Simon, Managing Director
Torreya“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”
Noemi Rosa
Novartis“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”